This is nearly a textbook example about how a news release can take mixed results from a clinical study and both highlight the promising findings while illuminating the harms and other issues, too. The only glaring omission here was any mention of the costs of treatment, which likely are considerable.
The release discusses a clinical trial of a therapy for multiple sclerosis (MS) that includes destruction of the immune system with chemotherapy and reconstitution of the immune system with previously preserved patient’s blood stem cells. The study is of 24 subjects followed from 4 to 13 years.
As the news release states, “MS affects approximately 2.3 million people around the world, causing symptoms that range from blurred vision to extreme fatigue to partial or complete paralysis.” This therapy is intended for only those with severe relapsing disease, but these are the people who become the most disabled the quickest and for whom specific MS drugs do not seem to work well.
There is no mention of the cost of this therapy. However, it is already used for treating leukemia and some other types of cancer and so the costs should be known. Because the treatment involves destruction of the immune system via chemotherapy and the use of stem cells, it is a very complex and intensive treatment requiring long hospital stays. This therapy is likely extremely expensive.
The release clearly indicates that all of the subjects showed benefits from the therapy with none of the patients requiring MS drugs, showing additional brain lesions or exhibiting a clinical relapse. It provided quantification in almost each of its bullet points on outcomes from the therapy. It also states that 40 percent of the subjects regained some of their lost function.
In the very first quote — the first quote! — the release talks about side effects. This is a huge departure from most news releases about clinical studies. It says, “This is very exciting. However, it is important to note that this therapy can have serious side effects and risks, and would only be appropriate for a small proportion of people with very active MS. People with MS who have had significant disability for a long time would likely not benefit.” So it acknowledges the risks and then goes beyond. These people will benefit. These people will not. You have to appreciate that clarity. The release also says later, “Indeed, one participant in this study died of liver failure due to the treatment and another required intensive care for liver complications. The treatment regimen was modified over the course of the study to reduce toxicity, but all participants still developed fevers, which were frequently associated with infections.”
The release explains all of the relevant details about the structure of the study, saying: “Led by Dr. Harold Atkins and Dr. Mark S. Freedman of The Ottawa Hospital and the University of Ottawa, the trial included 24 participants who were followed for up to 13 years.” By noting high up that the study was small on participants but long on duration it provides people with the right context for understanding how to weigh the evidence here.
There is no disease mongering in the release. And we like how the release took care to stratify the different levels of MS and not to talk about it as a monolithic disease. It was a good reminder for writers that people don’t experience diseases in one way and that diseases can change their character as they progress.
Very early in the release it notes who funded the study and — a rarity — how much the study cost. “The $6.47 million trial was funded by the MS Society of Canada and its affiliated Multiple Sclerosis Scientific Research Foundation. The research was also supported by The Ottawa Hospital Foundation, The Ottawa Hospital Department of Medicine and Canadian Blood Services.”
The release doesn’t mention any alternative treatments or compare how the new therapy compares with the standard treatments. The study does compare the patient volunteers’ individual outcomes before and after treatment.
The release establishes that the therapy is available at limited locations where it states, “People who are interested in this therapy should speak with their own neurologist, who can request a referral to The Ottawa Hospital MS Clinic or another major hospital with experience in this area….”
While acknowledging that the combined chemotherapy and stem cell intervention has been used previously, the release describes the novelty of this research as:
“Our study is unique in that we used a stronger cocktail of drugs to eliminate the immune system, we followed the participants for a very long time, and the majority of our participants have had significant, long-lasting responses.”
The release is cautious where it needs to be and provides the right context for readers to understand that these are promising findings but only for a small segment of the population.
Systematic, Criteria-Driven
A great read on this weekend’s NYT claims of a cure for Type 1.
Cure for Type 1 diabetes? We’ve been down this road before with NY Times https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
"But it is the framing and the emphasis of the #journalism by a leading science journalist at a leading newspaper that demands scrutiny. It has an impact on readers and on sick people that may cause harm by promoting false hope about extremely preliminary research"
👍👏💪 truth https://twitter.com/garyschwitzer/status/1465399358137024518
Why we should still miss healthnewsreview. https://twitter.com/garyschwitzer/status/1465399358137024518
Comments (1)
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
A Fisher
June 23, 2016 at 1:49 pmThe news release does not mention how the treatment, performed 13 years ago, differs from now prevailing methods. Indeed, the protocols have changed over the last 13 years to bring the mortality rate down, which is of utmost importance.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like